(IN BRIEF) Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines Prolia® and Xgeva®. The products target a range of conditions including osteoporosis, … Read the full press release
Posted in Business, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Biosimilar Development, biosimilar portfolio, Bomyntra, bone metastases, Conexxence, denosumab biosimilar, Dr. Sang-Jin Pak, EU approvals, European launch, Fresenius Kabi, Fresenius Kabi Advances Biosimilars Access in Europe with New Approvals for Conexxence and Bomyntra, global healthcare, KabiCare, LUMIADE-3 trial, oncology biosimilars, osteoporosis treatment, patient access, Prolia, RANKL inhibitor, skeletal related events, Xgeva
(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged #FutureFresenius, Biopharma platform, Bomyntra, cancer metastasis to bone, Conexxence, denosumab biosimilar, Europe, European Commission approval, Fresenius, Fresenius Kabi, Fresenius Kabi Deutschland GmbH, giant cell tumor of bone, high-quality biosimilars, osteoporosis, postmenopausal women, registered trademarks, skeletal complications, treatment-related bone loss
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?